eferences
- Allen L, Kimura K, McKichan J, Ritschel WA. Manual of symbols, equations & definitions in pharmacokinetics. Journal of Clinical Pharmacology 1982; 22: 1S–23S
- Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin. Journal of Pharmacokinetics and Biopharmaceutics 1980; 8: 165–176
- Charter MK. The estimation of moments: A technical note. Journal of Pharmacokinetics and Biopharmaceutics 1989; 17: 203–208
- Curtis CG, Cross SAM, McCulloch RJ, Powell GM. Whole-body autoradiography. Academic Press, London 1981
- Duhm B, Maul W, Medenwald H, Patzschke K, Wegner LA. [Animal experiments on pharmacokinetic and biotransformation of radioactively labelled 4-(2′-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethly ester]. Arzneimittelforschung 1972; 22: 42, [in German]
- FDA. Analytical procedures and methods validation: Chemistry, manufacturing, and controls. Federal Register 2000; 65: 52776–52777, (Notices)
- Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Multiple dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct Factor Xa inhibitor in healthy male subjects. Blood 2003; 102, abst 3004
- Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939 – an oral, direct factor Xa inhibitor. Clinical Pharmacology and Therapeutics 2005, in press
- Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism and Disposition 1998; 26: 1202–1212
- Mann KG, Brummel K, Butenas S. What is all that thrombin for?. Journal of Thrombosis and Haemostasis 2003; 1: 1504–1514
- Perzborn EP, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 — an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis 2005; 3: 514–521
- Petitpas J, Bhattacharya A, Twine S, East M, Curry S. Crystal structure analysis of Warfarin binding to human serum albumin. Journal of Biological Chemistry 2001; 276: 22804–22809
- Rowland M, Tozer TN. Clinical pharmacokinetics — concepts and applications, 3rd ed. Williams & Wilkins, Baltimore, PA 1995
- Scholtan W, Schmid J. Die Bindung der Penecilline an die Eiweisskörper des Serums und des Gewebes. Arzneimittelforschung 1963; 12: 741–750, [in German]
- Vorum H, Honore B. Influence of fatty acids on the binding of Warfarin and Phenprocoumon to human serum albumin with relation to anticoagulant therapy. Journal of Pharmacy and Pharmacology 1996; 48: 870–875
- Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U. In vitro metabolism of BAY 59-7939 — an oral direct Factor Xa inhibitor. Drug Metabolism Reviews 2004a; 36: 98, (Suppl. 1), (abst 195)
- Weinz C, Schwarz T, Pleiss U, Schmeer K, Kubitza D, Mueck W, Gondol D, Aitken H. Metabolism and distribution of [14C]BAY 59-7939 — an oral, direct Factor Xa inhibitor — in rat, dog, and human. Drug Metabolism Reviews 2004b; 36: 98, (Suppl. 1), (abst 196)
- Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1978; 6: 547–558